Who Is Eligible for Lupus Clinical Trials?
Most lupus trials require a confirmed SLE diagnosis meeting ACR or EULAR classification criteria, with active disease at enrollment — typically measured by a SLEDAI score above a defined threshold. Unlike RA, lupus trials often have complex eligibility rules around organ involvement:
- Trials for mild to moderate SLE focus on skin, joint, and constitutional symptoms — lower disease activity scores required
- Trials for moderate to severe SLE require higher SLEDAI scores, often with ongoing corticosteroid use
- Trials for lupus nephritis require kidney biopsy confirmation of active nephritis (Class III, IV, or V)
- Trials for refractory SLE are targeting patients who have failed hydroxychloroquine, immunosuppressants, and at least one biologic
Most trials require that you are on a stable dose of hydroxychloroquine (or have documented intolerance) and allow background immunosuppressants like mycophenolate or azathioprine.
If you have kidney involvement confirmed by biopsy, there are trials specifically designed for lupus nephritis that are separate from general SLE trials. These often offer access to therapies years before FDA approval. Search above and look for trials that mention "nephritis" or filter by "lupus nephritis" on ClinicalTrials.gov.
What Treatments Are Currently Being Tested?
| Drug Class | Mechanism | Target Population |
|---|---|---|
| Type I interferon inhibitors | Block the interferon pathway that is overactive in most lupus patients | Moderate to severe SLE, positive interferon signature |
| BLyS/APRIL dual inhibitors | Block survival signals for autoreactive B cells that produce lupus autoantibodies | Active SLE with positive ANA or anti-dsDNA |
| CD19/CD20 B cell depleters | Eliminate autoreactive B cells — obinutuzumab and others in this class | Lupus nephritis, refractory SLE |
| CAR-T cell therapy | Resets the immune system — early results show drug-free remission in some patients | Severe refractory SLE, failed multiple therapies |
| Calcineurin inhibitors (combinations) | Voclosporin and similar agents combined with standard induction therapy | Active lupus nephritis |
| JAK inhibitors | Block intracellular signaling pathways driving lupus inflammation | Cutaneous lupus, moderate SLE |
The CAR-T Opportunity in Lupus
CAR-T cell therapy — which uses engineered immune cells to reset the immune system — has shown remarkable early results in small cohorts of severe lupus patients, with some achieving drug-free remission for the first time. These are Phase 1 trials at specialized academic centers with strict eligibility, but they represent a genuinely novel treatment paradigm.
If you have severe, refractory lupus that has not responded to multiple treatments including biologics, ask your rheumatologist whether a CAR-T trial might be appropriate. These trials require referral to a specialized center and have intensive monitoring requirements.
What to Expect as a Trial Participant
Lupus trials typically run 52 weeks for the main phase, with many offering 2-3 year open-label extensions. The monitoring is more intensive than standard care — this means more lab draws and clinic visits, but also earlier detection of flares and complications.
- Screening: Labs (CBC, CMP, complement, anti-dsDNA, urinalysis), SLEDAI assessment, review of medical history
- Baseline: Formal enrollment and randomization — most trials are double-blind
- Treatment visits: Every 4-8 weeks typically, with labs at each visit
- Kidney biopsy: Required at baseline for nephritis trials, sometimes at week 52 as a secondary endpoint
- Compensation: Most sites compensate $75-$250 per visit for time and travel
If You Are Struggling to Afford Treatment
Access to biologics like belimumab and anifrolumab remains a significant barrier for many lupus patients due to cost. Clinical trials offer an important access pathway — the investigational drug, all related monitoring, and labs are provided at no cost throughout the trial. For patients with active disease who cannot access or afford standard-of-care biologics, trials may represent the best available treatment option.
Frequently Asked Questions
Other Rheumatology Trials
Trial data sourced live from ClinicalTrials.gov. Content reviewed by Mahiar Rabie, MS, MD. This page is for informational purposes only and does not constitute medical advice. Eligibility for any specific trial must be confirmed with the trial coordinator.